Combination treatment before surgery for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with triple-negative breast cancer that has not spread to other parts of the body.
- You have not had surgery, chemotherapy, radiation, or other treatments for this breast cancer yet.
- You are generally in good health, with a performance status of 0 or 1 (able to carry on daily activities).
- You are willing to provide a sample of your tumor tissue for testing.
- You agree to participate in a related observational study (PROGECT).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests a combination of targeted therapies (pertuzumab and trastuzumab) and hormone therapy (palbociclib and exemestane) given before surgery for triple-positive breast cancer. The goal is to see if this package effectively shrinks the tumor and improves outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.